Regenerating gene family members 1 (REG Ia) and 4 (REG IV) are overexpressed in a subset of gastric cancers. However, comparative characterization of the expression of these family proteins has remained unclear. Therefore, we aimed to elucidate not only the association between REG protein expression and mucin phenotype but also their significance as a prognostic marker for patients with gastric cancer. The expression of REG Ia, REG IV, CDX2, MUC2, and MUC5AC in gastric cancer tissues was examined by immunohistochemistry. The relationship between REG protein expression and clinicopathological parameters or mucin phenotype was then analyzed. REG Ia and REG IV expression was positive in 33 (52%) and 31 (49%) of 63 gastric cancers examined, respectively. REG Ia expression was significantly related to venous invasion and tumor stage, whereas REG IV expression showed no relationship to clinicopathological features. With regard to mucin phenotype, REG IV expression was significantly correlated with MUC2 and CDX2 expression, suggesting an association with the intestinal mucin phenotype of gastric cancer. On the other hand, REG Ia expression had no correlation with MUC2, CDX2, or MUC5AC in gastric cancer tissues. Expression of REG Ia but not REG IV was an independent predictor of poor outcome in patients with gastric cancer. In addition, patients with gastric cancer negative for both REG Ia and REG IV expression had a significantly better outcome than patients positive for either REG Ia or REG IV. Profiling of REG protein expression is useful to for prognostication of patients with gastric cancer. Modern Pathology ( The regenerating gene (Reg) was originally isolated from regenerating rat pancreatic islets, 1 and its gene product was shown to have a trophic effect on not only islet but also gastric epithelial cells.
The regenerating gene (Reg) was originally isolated from regenerating rat pancreatic islets, 1 and its gene product was shown to have a trophic effect on not only islet but also gastric epithelial cells. 2, 3 Recently, many Reg-related genes have been isolated and shown to constitute a multigene family. 4 Among human REG family proteins, REG Ia and REG IV are reportedly overexpressed in a subset of gastric cancer. [5] [6] [7] [8] [9] Moreover, several microarray analyses have recently isolated REG Ia and REG IV as novel genes that are overexpressed in gastric cancer tissues, 10, 11 suggesting that both genes have important functions in gastric carcinogenesis. Indeed, we have previously clarified that REG Ia acts as a trophic and/or anti-apoptotic factor in the development of gastric cancer, 12 and others have reported that REG IV protein confers cell resistance to chemotherapeutic agents, 9 suggesting that these proteins are both associated with tumor progression. It is noteworthy that in non-neoplastic tissues REG Ia and REG IV are commonly expressed not only in endocrine cells but also in metaplastic cells that frequently accompany gastric cancer lesions, 5, 8, 12, 13 implying a possible link between REG protein expression and mucin phenotype of gastric lesions. In addition, there is increasing speculation as to whether REG Ia and REG IV protein expression may be applicable as a prognostic marker for patients with various malignancies. 6, 7, 9, 14, 15 However, comparative characterization of the expression of these proteins in gastric cancer tissues has not yet been carried out. Therefore, in this study, we attempted to clarify not only the association between REG protein expression and mucin phenotype but also their prognostic significance in patients with gastric cancer.
Materials and methods

Patients, Tissue Samples, and Histology
Sixty-three patients with gastric cancer (42 men, 21 women; mean age 65.3, range 36-83 years) who underwent surgery at Dokkyo University School of Medicine between 1997 and 2001 were enrolled. Patients with other malignant diseases were excluded, as were patients who had received preoperative treatment such as chemotherapy and radiation therapy. This study was carried out with the approval of the Dokkyo University Surgical Pathology Committee, and informed consent was obtained from all patients.
The resected specimens were fixed in 10% neutral buffered formalin and embedded in paraffin. Multiple hematoxylin-eosin-stained sections of all 63 lesions were examined. The tissue sections including the invasive front of tumor were subjected to immunostaining. The following factors were determined for all patients and lesions: age, sex, tumor location, Lauren's histological classification, tumor invasion, lymph node metastases, and patient survival. The tumor stage was according to the International Union Against Cancer TNM staging system. 16 The clinicopathological features of the patients were summarized in Table 1 .
Immunohistochemistry
Immunohistochemical staining for REG Ia, REG IV, CDX2, MUC2, and MUC5AC was performed with a LSAB-2 kit (Dako, Marseille, France) as described previously. 5 In brief, 4-mm-thick sections were placed on slides, deparaffinized, and dehydrated. They were then placed in 0.01 mol/l citrate buffer (pH 6.0) and treated by microwave heating (MI-77; Azumaya, Tokyo, Japan; 400 W, 951C) for 10 and 40 min to facilitate antigen retrieval for REG Ia and Ki-67, respectively, whereas they received no treatment with microwave heating for the immunostaining of ssDNA. Then, the sections were followed by pretreatment with 0.3% H 2 O 2 in methanol for 20 min at room temperature to quench endogenous peroxidase activity. The sections were incubated with 1% bovine serum albumin in phosphatebuffered saline (PBS) for 30 min, and then with anti-REG Ia (dilution 1:1000), anti-REG IV (R&D Systems, Minneapolis, MN, USA; dilution 1:50), anti-CDX2 (BioGenex, San Ramon, CA, USA; dilution 1:20), anti-MUC2 (Novocastra, Newcastle, UK; dilution 1:100), and anti-MUC5AC (Novocastra; dilution 1:100) for 1 h. Thereafter, the sections were incubated with biotinylated secondary antibody for 15 min, washed with PBS, and treated with peroxidase-conjugated streptavidin for 20 min. Finally, the sections were incubated in 3,3 0 -diaminobenzidine tetrahydrochloride with 0.05% H 2 O 2 for 3 min and then counterstained with Mayer's hematoxylin. The monoclonal antibody for human REG Ia protein was generated as previously reported, against human REG Ia protein corresponding to positions 23-166 of the deduced human REG Ia protein. 17 The specificity of the antibody was proven not only by western blot analysis 17 but also by immunohistochemistry. 18 The percentage of cancer cells stained with each antibody was evaluated. A result was considered positive if at least 10% of cells were stained. 8 When fewer than 10% of cancer cells were stained, immunostaining was considered negative. For mucin-phenotype analysis, gastric cancers were classified into four groups as follows: G-type, positive for MUC5AC alone; I-type, positive for MUC2 alone; GI-type, positive for both MUC5AC and MUC2; N-type, negative for both MUC5AC and MUC2. 
Statistical Analysis
Statview 5.0J statistical software (Abacus Concepts Inc., Berkeley, CA, USA) was used for all analyses. w 2 -Analyses were performed to investigate the relationship between REG proteins expression and clinicopathological features or immunohistochemical data. All values were expressed as the mean±s.e.m., and the significance of differences between two groups was assessed using MannWhitney U-test. Overall survival rate was calculated using the Kaplan-Meier method and analyzed by the log-rank test. Univariate and multivariate Cox regression analyses were used to examine whether REG protein expression was an independent predictor of overall survival. The significant predictors identified in univariate analysis were then subjected to multivariate analysis. The level of statistical significance was set at Po0.05.
Results
Relationship Between REG Protein Expression and Clinicopathological Features in Patients with Gastric Cancer
Immunoreactivity for REG Ia and REG IV proteins was detected in various types of gastric cancer ( Figure 1 ). REG Ia and REG IV proteins were both detected in goblet-like vesicles or in the perinuclear region of gastric cancer cells.
Of the 63 gastric cancer tissue samples examined, 33 (52%) and 31 (49%) were positive for REG Ia and REG IV proteins, respectively. As shown in Figure  1e and f, some gastric cancers were positive for both REG Ia and REG IV proteins. Indeed, expression of REG Ia tended to correlate with that of REG IV in the gastric cancer tissues examined (Table 2) . With regard to clinicopathological features, REG Ia expression was significantly associated with the prevalence of venous invasion and high tumor stage, whereas REG IV expression showed no relationship to any of the clinicopathological features investigated (Table 3) .
Relationship Between REG Protein Expression and Mucin Phenotype in Gastric Cancer
We investigated the association between REG protein expression and mucin phenotype using gastric and intestinal mucin markers. Gastric and intestinal markers were detected in 44 of 63 (70%) cases for MUC5AC, 32 (51%) cases for MUC2, and 44 (70%) cases for CDX2. Positivity for REG IV protein was significantly correlated with positivity for MUC2 and CDX2 in gastric cancer tissues ( Figure 2 , Table 4 ). However, positivity for REG Ia protein showed no correlation with MUC2, CDX2, or MUC5AC, although it showed a tendency to be correlated with CDX2 expression.
On the basis of the expression of MUC5AC and MUC2, we classified the 63 gastric cancers phenotypically as G-type (22; 35%), I-type (10; 16%), GI-type (22; 35%), and N-type (9; 14%). REG IVpositive gastric cancer was significantly of the GI-type (18 of 31; 58%, Po0.001). In addition, REG IV-positive gastric cancer tented to be of the I-type (7 of 31; 23%, P ¼ 0.151). However, REG Ia-positive cancer showed no specific mucin phenotype (Table 5) .
Prognostic Value of REG Protein Expression in Patients with Gastric Cancer
To evaluate the prognostic significance of REG protein expression in patients with gastric cancer, we constructed Kaplan-Meier curves (Figure 3) . We found that patients with REG Ia-positive gastric cancer had a significantly worse outcome than those without (Figure 3a ). In addition, the patients with REG IV-positive gastric cancer tended to show a poor outcome, but not to a significant degree (Figure 3b) .
We next examined whether REG Ia expression was an independent factor predictive of overall survival in patients with gastric cancer. Univariate analysis indicated that venous invasion, lymph node metastasis, tumor stage, and REG Ia expression were significantly predictive of overall survival. Moreover, multivariate analysis revealed that tumor stage and REG Ia expression were independently predictive of overall survival (Table 6) .
Finally, we investigated whether combination of REG Ia and REG IV expression was of value for prognostication of patients with gastric cancer. Interestingly, patients who were negative for both REG Ia and REG IV showed a significantly better outcome than patients in the other groups (Figure 4) . Moreover, double negative expression of REG Ia and REG IV was independently predictive of overall survival in patients with gastric cancer when subjected to multivariate Cox regression, including factors such as venous invasion, lymph node metastasis, and tumor stage (P ¼ 0.0076, hazard ratio ¼ 8.403, 95% confidence interval 1.761-40.000).
Discussion
REG family proteins commonly possess three disulfide bonds among six conserved cysteine residues and form a Drickamer motif that is common in the calcium-dependent lectin (C-type lectin) superfamily. 19 At present, REG family proteins are classified into four subfamilies according to their primary structures, 20 and their overexpression has been reported in neoplastic or inflamed tissues in various organs including the stomach, colorectum, bile duct, and pancreas. [5] [6] [7] [8] 14, 21, 22 Interestingly, microarray analyses suggest that expression of the REG Ia and REG Ia and REG IV in gastric cancer H Yamagishi et al REG IV genes is prominently upregulated during the development of gastric cancer, 10, 11 and in fact we found immunohistochemically that not only REG Ia but also REG IV protein was overexpressed in a considerable number of gastric cancers. However, we also found that REG Ia and REG IV were not always coexpressed in a subset of gastric cancers. Thus, although REG Ia and REG IV proteins belong In this study, we focused on the association between REG protein expression and the mucin phenotype of the gastric cancer because REG proteins are commonly expressed in the goblet or metaplastic cells that produce abundant mucin in the gastrointestinal tract. 8, 12 Compatible with a previous report, 8 REG IV expression was significantly associated with the intestinal mucin phenotype of gastric cancer. However, we found no association between REG Ia expression and gastrointestinal mucin-phenotype markers, MUC2 or MUC5AC, in gastric cancers. Although we cannot explain this discrepancy, the regulatory mechanisms of REG Ia and REG IV expression may differ. With regard to REG Ia expression in gastric cancer cells, STAT3 signaling is suggested to be crucial in vitro; 23 on the other hand, EGFR signaling is closely associated with REG IV expression not only in gastric but also in colorectal cancer cells. 9, 24, 25 Moreover, immunohistochemical analyses revealed that REG Ia and REG IV expression is indeed associated with phosphorylated STAT3 and EGFR expression in gastric cancer tissues, respectively. 9, 23 Although the clinicopathological significance of REG protein expression is not fully understood, it may be interesting for practical use to consider REG Ia and REG IV as biomarkers of intracellular signaling rather than of the mucin phenotype.
Accumulating evidence suggests that REG Ia and REG IV commonly have functions in tumor progression by exerting trophic and/or anti-apoptotic effects on gastric cancer cells. 12, 24, 25 Accordingly, another important question is whether REG Ia and REG IV proteins are reliable markers for prognostication of patients with gastric cancer. We found that REG Ia but not REG IV is an independent prognostic marker for patients with gastric cancer. On the other hand, we also found that patients with REG IV-positive gastric cancer tended to show a poor outcome, although not to a statistically significant degree. Therefore, we also investigated whether a combination of REG Ia and REG IV expression would be beneficial for more precise prediction of outcome in patients with gastric cancer. In comparison with REG Ia alone, combination of REG Ia and REG IV did not dramatically improve the predictive ability. However, combination of the two REG proteins was clearly advantageous for distinguishing Table 3 Relationship between REG protein expression and clinicopathological features in patients with gastric cancer Number of REG Ia-positive patients/total number of patients
P-value
Number of REG IV-positive patients/total number of patients Values are the number of cases (P ¼ 0.0577).
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between good and poor outcome in the REG Ia-negative group. Interestingly, 9 Mitani et al. have reported that REG IV expression does not predict patient survival, but significantly predicts resistance to chemotherapeutic agents. In this regard, we favor the combination of REG Ia and REG IV rather than REG Ia alone for strict delineation of patients with gastric cancer who are likely to have a poor outcome. In summary, our present data show that REG Ia expression, having no association with gastrointestinal mucin phenotype, is a significantly useful prognostic marker in patients with gastric cancer when compared with REG IV expression in association with the intestinal mucin phenotype in such patients. On the other hand, it is noteworthy that REG IV expression appears to be a good marker for predicting susceptibility to chemotherapy in patients with gastric cancer, 9 although this issue with regard to REG Ia expression still remains to be elucidated. Therefore, in the further studies we would like to investigate whether the profiling of REG protein expression is useful not only for prognostication but also for providing individualized treatment in patients with gastric cancer. 
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